Each vial contains 250 ug of romiplostim. After reconstitution, a deliverable volume of 0.5 ml solution contains 250 ug of romiplostim (500 ug/ml). An additional overfill is included in each vial to ensure that 250 ug of romiplostim can be delivered. Romiplostim is produced by recombinant DNA technology in Escherichia coli (E. coli). For the full list of excipients, see section 6.1.

PHARMACEUTICAL FORM

CLINICAL PARTICULARS

Posology and method of administration

Treatment should remain under the supervision of a physician who is experienced in the treatment of haematological diseases.

A subject's actual body weight at initiation of therapy should be used to calculate dose. The once weekly dose of romiplostim should be increased by increments of 1 mg/kg until the patient achieves a platelet count >= 50 x 109/l. Platelet counts should be assessed weekly until a stable platelet count (>= 50 x 109/l for at least 4 weeks without dose adjustment) has been achieved. Platelet counts should be assessed monthly thereafter. A maximum once weekly dose of 10 mg/kg should not be exceeded. Adjust the dose as follows:

Due to the interindividual variable platelet response, in some patients platelet count may abruptly fall below 50 x 109/l after dose reduction or treatment discontinuation. In these cases, if clinically appropriate, higher cut-off levels of platelet count for dose reduction (200 x 109/l) and treatment interruption (400 x 109/l) may be considered according to medical judgement. A loss of response or failure to maintain a platelet response with romiplostim within the recommended dosing range should prompt a search for causative factors (see section 4.4, loss of response to romiplostim).

Treatment with romiplostim should be discontinued if the platelet count does not increase to a level sufficient to avoid clinically important bleeding after four weeks of romiplostim therapy at the highest weekly dose of 10 mg/kg. Patients should be clinically evaluated periodically and continuation of treatment should be decided on an individual basis by the treating physician. The reoccurrence of thrombocytopenia is likely upon discontinuation of treatment (see section 4.4).

No overall differences in safety or efficacy have been observed in patients < 65 and >= 65 years of age (see section 5.1). Although based on these data no adjustment of the dosing regimen is required for older patients, care is advised considering the small number of elderly patients included in the clinical trials so far.

The safety and efficacy of Romiplostim in children aged under 18 years has not yet been established. No data are available.

Romiplostim should not be used in patients with moderate to severe hepatic impairment (Child-Pugh score >= 7) unless the expected benefit outweighs the identified risk of portal venous thrombosis in patients with thrombocytopenia associated to hepatic insufficiency treated with thrombopoietin (TPO) agonists (see section 4.4). If the use of romiplostim is deemed necessary, platelet count should be closely monitored to minimise the risk of thromboembolic complications.

No formal clinical trials have been conducted in these patient populations. Nplate should be used with caution in these populations.

For subcutaneous use. After reconstitution of the powder, Nplate solution for injection is administered subcutaneously. The injection volume may be very small. Caution should be used during preparation of Nplate in calculating the dose and reconstitution with the correct volume of sterile water for injection. Special care should be taken to ensure that the appropriate volume of Nplate is withdrawn from the vial for subcutaneous administration - a syringe with graduations of 0.01 ml should be used. For instructions on reconstitution of the medicinal product before administration, see section 6.6.

Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 or to E. coli derived proteins.

Special warnings and precautions for use

Thrombocytopenia is likely to reoccur upon discontinuation of treatment with romiplostim. There is an increased risk of bleeding if romiplostim treatment is discontinued in the presence of anticoagulants or anti-platelet agents. Patients should be closely monitored for a decrease in platelet count and medically managed to avoid bleeding upon discontinuation of treatment with romiplostim. It is recommended that, if treatment with romiplostim is discontinued, ITP treatment be restarted according to current treatment guidelines. Additional medical management may include cessation of anticoagulant and/or antiplatelet therapy, reversal of anticoagulation, or platelet support.

Increased bone marrow reticulin is believed to be a result of TPO receptor stimulation, leading to an increased number of megakaryocytes in the bone marrow, which may subsequently release cytokines. Increased reticulin may be suggested by morphological changes in the peripheral blood cells and can be detected through bone marrow biopsy. Therefore, examinations for cellular morphological abnormalities using peripheral blood smear and complete blood count (CBC) prior to and during treatment with romiplostim are recommended. See section 4.8 for information on the increases of reticulin observed in romiplostim clinical trials. If a loss of efficacy and abnormal peripheral blood smear is observed in patients, administration of romiplostim should be discontinued, a physical examination should be performed, and a bone marrow biopsy with appropriate staining for reticulin should be considered. If available, comparison to a prior bone marrow biopsy should be made. If efficacy is maintained and abnormal peripheral blood smear is observed in patients, the physician should follow appropriate clinical judgment, including consideration of a bone marrow biopsy, and the risk-benefit of romiplostim and alternative ITP treatment options should be re-assessed.

Platelet counts above the normal range present a risk for thrombotic/thromboembolic complications. The incidence of thrombotic/thromboembolic events observed in clinical trials was 6.0% with romiplostim and 3.6% with placebo. Caution should be used when administering romiplostim to patients with known risk factors for thromboembolism including but not limited to inherited (e.g. Factor V Leiden) or acquired risk factors (e.g. ATIII deficiency, antiphospholipid syndrome), advanced age, patients with prolonged periods of immobilisation, malignancies, contraceptives and hormone replacement therapy, surgery/trauma, obesity and smoking. Cases of thromboembolic events (TEEs), including portal vein thrombosis, have been reported in patients with chronic liver disease receiving romiplostim. Romiplostim should be used with caution in these populations. Dose adjustment guidelines should be followed (see section 4.2).

Medication errors including overdose and underdose have been reported in patients receiving Nplate, dose calculation and dose adjustment guidelines should be followed (see section 4.2). Overdose may result in an excessive increase in platelet counts associated with thrombotic/thromboembolic complications. If the platelet counts are excessively increased, discontinue Nplate and monitor platelet counts. Reinitiate treatment with Nplate in accordance with dosing and administration recommendations. Underdose may result in lower than expected platelet counts and potential for bleeding. Platelet counts should be monitored in patients receiving Nplate (see sections 4.2, 4.4 and 4.9).

A positive benefit/risk for romiplostim is only established for the treatment of thrombocytopenia associated with chronic ITP and romiplostim must not be used in other clinical conditions associated with thrombocytopenia. The diagnosis of ITP in adults and elderly patients should have been confirmed by the exclusion of other clinical entities presenting with thrombocytopenia, in particular the diagnosis of MDS must be excluded. A bone marrow aspirate and biopsy should normally have been done over the course of the disease and treatment, particularly in patients over 60 years of age, for those with systemic symptoms or abnormal signs such as increased peripheral blast cells. In clinical studies of treatment with romiplostim in patients with MDS, cases of transient increases in blast cell counts were observed and cases of MDS disease progression to AML were reported. In a randomized placebo-controlled trial in MDS subjects, treatment with romiplostim was prematurely stopped due to a numerical excess of disease progression to AML and an increase in circulating blasts greater than 10% in patients receiving romiplostim. Of the cases of MDS disease progression to AML that were observed, patients with RAEB-1 classification of MDS at baseline were more likely to have disease progression to AML compared to lower risk MDS. Romiplostim must not be used for the treatment of thrombocytopenia due to MDS or any other cause of thrombocytopenia other than ITP outside of clinical trials.

A loss of response or failure to maintain a platelet response with romiplostim treatment within the recommended dosing range should prompt a search for causative factors, including immunogenicity (see section 4.8) and increased bone marrow reticulin (see above).

Alterations in red (decrease) and white (increase) blood cell parameters have been observed in non- clinical toxicology studies (rat and monkey) but not in ITP patients. Monitoring of these parameters should be considered in patients treated with romiplostim.

Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed. The potential interactions of romiplostim with co- administered medicinal products due to binding to plasma proteins remain unknown. Medicinal products used in the treatment of ITP in combination with romiplostim in clinical trials included corticosteroids, danazol, and/or azathioprine, intravenous immunoglobulin (IVIG), and anti-D immunoglobulin. Platelet counts should be monitored when combining romiplostim with other medicinal products for the treatment of ITP in order to avoid platelet counts outside of the recommended range (see section 4.2). Corticosteroids, danazol, and azathioprine use may be reduced or discontinued when given in combination with romiplostim (see section 5.1). Platelet counts should be monitored when reducing or discontinuing other ITP treatments in order to avoid platelet counts below the recommended range (see section 4.2).

Fertility, pregnancy and lactation

There are no or limited amount of data from the use of romiplostim in pregnant women. Studies in animals have shown reproductive toxicity

foetal platelet counts in rats (see section 5.3). Romiplostim is not recommended during pregnancy and in women of childbearing potential not using contraception.

It is unknown whether romiplostim/metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from romiplostim therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.

Effects on ability to drive and use machines

Nplate has moderate influence on the ability to drive and use machines. In clinical trials, mild to moderate, transient bouts of dizziness were experienced by some patients.

Undesirable effects

Summary of the safety profile

Based on an analysis of all adult ITP patients receiving romiplostim in 4 controlled and 5 uncontrolled clinical trials, the overall subject incidence of all adverse reactions for romiplostim-treated subjects was 91.5% (248/271). The mean duration of exposure to romiplostim in this study population was 50 weeks. The most serious adverse reactions that may occur during Nplate treatment include: reoccurrence of thrombocytopenia and bleeding after cessation of treatment, increased bone marrow reticulin, thrombotic/thromboembolic complications, medication errors and progression of existing MDS to AML. The most common adverse reactions observed include hypersensitivity reactions (including cases of rash, urticaria and angioedema) and headache.

Tabulated list of adverse reactions

Frequencies are defined as: very common (>= 1/10), common (>= 1/100 to < 1/10), uncommon (>= 1/1000 to < 1/100), rare (>= 1/10,000 to < 1/1,000); very rare (< 1/10,000) and not known (cannot be estimated from the available data). Within each MedDRA system organ class and frequency grouping, undesirable effects are presented in order of decreasing incidence.

MedDRA system organ class	Very common	Common	Uncommon
Infections and infestations	Upper respiratory tract infection	Gastroenteritis	Influenza Localised infection Nasopharyngitis
Neoplasms benign, malignant and unspecified (including cysts and polyps)			Multiple myeloma Myelofibrosis
Blood and lymphatic system disorders		Bone marrow disorder * Thrombocytopenia *	Anaemia Aplastic anaemia Bone marrow failure Leukocytosis Splenomegaly Thrombocythaemia Platelet count increased Platelet count abnormal
Immune system disorder	Hypersensitivity * *	Angioedema
MedDRA system organ class	Very common	Common	Uncommon
Metabolism and nutrition disorders			Alcohol intolerance Anorexia Decreased appetite Dehydration Gout
Psychiatric disorders		Insomnia	Depression Abnormal dreams
Nervous system disorders	Headache	Dizziness Migraine Paraesthesia	Clonus Dysgeusia Hypoaesthesia Hypogeusia Neuropathy peripheral Transverse sinus thrombosis
Eye disorders			Conjunctival haemorrhage Accommodation disorder Blindness Eye disorder Eye pruritus Lacrimation increased Papilloedema Visual disturbances
Ear and labyrinth disorders			Vertigo
Cardiac disorders		Palpitations	Myocardial infarction Heart rate increased
Vascular disorders		Flushing	Deep vein thrombosis Hypotension Peripheral embolism Peripheral ischaemia Phlebitis Thrombophlebitis superficial Thrombosis Erythromelalgia
Respiratory, thoracic and mediastinal disorders		Pulmonary embolism *	Cough Rhinorrhoea Dry throat Dyspnoea Nasal congestion Painful respiration
Gastrointestinal disorders		Nausea Diarrhoea Abdominal pain Constipation Dyspepsia	Vomiting Rectal haemorrhage Breath odour Dysphagia Gastro-oesophageal reflux disease Haematochezia Mouth haemorrhage Stomach discomfort Stomatitis Tooth discolouration
MedDRA system organ class	Very common	Common	Uncommon
Hepatobiliary disorders			Portal vein thrombosis Increase in transaminase
Skin and subcutaneous tissue disorders		Pruritus Ecchymosis Rash	Alopecia Photosensitivity reaction Acne Dermatitis contact Dry skin Eczema Erythema Exfoliative rash Hair growth abnormal Prurigo Purpura Rash papular Rash pruritic Skin nodule Skin odour abnormal Urticaria
Musculoskeletal and connective tissue disorders		Arthralgia Myalgia Muscle spasms Pain in extremity Back pain Bone pain	Muscle tightness Muscular weakness Shoulder pain Muscle twitching
Renal and urinary disorders			Protein urine present
Reproductive system and breast disorders			Vaginal haemorrhage
General disorders and administration site conditions		Fatigue Oedema peripheral Influenza like illness Pain Asthenia Pyrexia Chills Injection site reaction	Injection site haemorrhage Chest pain Irritability Malaise Face oedema Feeling hot Feeling jittery
Investigations			Blood pressure increased Blood lactate dehydrogenase increased Body temperature increased Weight decreased Weight increased
Injury, poisoning and procedural complications		Contusion

* see section 4.4 * * Hypersensitivity reactions including cases of rash, urticaria, and angioedema

Description of selected adverse reactions

In addition the reactions listed below have been deemed to be related to romiplostim treatment.

Thrombocytosis

Based on an analysis of all adult ITP patients receiving romiplostim in 4 controlled and 5 uncontrolled clinical trials, 3 events of thrombocytosis were reported, n = 271. No clinical sequelae were reported in association with the elevated platelet counts in any of the 3 subjects.

Thrombocytopenia after cessation of treatment

Based on an analysis of all adult ITP patients receiving romiplostim in 4 controlled and 5 uncontrolled clinical trials, 4 events of thrombocytopenia after cessation of treatment were reported, n = 271 (see section 4.4).

Progression of existing Myelodysplastic Syndromes (MDS)

In a randomized placebo-controlled trial in MDS subjects treatment with romiplostim was prematurely stopped due to a numerical increase in cases of MDS disease progression to AML and transient increases in blast cell counts in patients treated with romiplostim compared to placebo. Of the cases of MDS disease progression to AML that were observed, patients with RAEB-1 classification of MDS at baseline were more likely to have disease progression to AML (see section 4.4). Overall survival was similar to placebo.

Increased bone marrow reticulin

In clinical trials, romiplostim treatment was discontinued in 4 of the 271 patients because of bone marrow reticulin deposition. In 6 additional patients reticulin was observed upon bone marrow biopsy (see section 4.4).

Immunogenicity

Clinical trials in adult ITP patients examined antibodies to romiplostim. While 5.8% and 3.9% of the subjects were positive for developing binding antibodies to romiplostim and TPO respectively, only 2 subjects (0.4%) were positive for neutralizing antibodies to romiplostim but these antibodies did not cross react with endogenous TPO. Both subjects tested negative for neutralising antibodies to romiplostim at 4 months after the end of dosing. The incidence of pre- existing antibodies to romiplostim and TPO was 8.0% and 5.4%, respectively. As with all therapeutic proteins, there is a potential for immunogenicity. If formation of neutralising antibodies is suspected, contact the local representative of the Marketing Authorisation Holder (see section 6 of the Package Leaflet) for antibody testing.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via .

the national reporting system

listed in

Appendix V

Overdose

No adverse effects were seen in rats given a single dose of 1000 mg/kg or in monkeys after repeated administration of romiplostim at 500 ug/kg (100 or 50 times the maximum clinical dose of 10 ug/kg, respectively). In the event of overdose, platelet counts may increase excessively and result in thrombotic/thromboembolic complications. If the platelet counts are excessively increased, discontinue Nplate and monitor platelet counts. Reinitiate treatment with Nplate in accordance with dosing and administration recommendations (see sections 4.2 and 4.4).

PHARMACOLOGICAL PROPERTIES

Pharmacodynamic properties

Pharmacotherapeutic group: Antihaemorrhagics, other systemic hemostatics, ATC code: B02BX04 Mechanism of action Romiplostim is an Fc-peptide fusion protein (peptibody) that signals and activates intracellular transcriptional pathways via the TPO receptor (also known as cMpl) to increase platelet production. The peptibody molecule is comprised of a human immunoglobulin IgG1 Fc domain, with each single- chain subunit covalently linked at the C-terminus to a peptide chain containing 2 TPO receptor- binding domains. Romiplostim has no amino acid sequence homology to endogenous TPO. In pre-clinical and clinical trials no anti-romiplostim antibodies cross reacted with endogenous TPO.

The safety and efficacy of romiplostim have been evaluated for up to 3 years of continuous treatment. In clinical trials, treatment with romiplostim resulted in dose-dependent increases in platelet count. Time to reach the maximum effect on platelet count is approximately 10-14 days, and is independent of the dose. After a single subcutaneous dose of 1 to 10 ug/kg romiplostim in ITP patients, the peak platelet count was 1.3 to 14.9 times greater than the baseline platelet count over a 2 to 3 week period and the response was variable among patients. The platelet counts of ITP patients who received 6 weekly doses of 1 or 3 ug/kg of romiplostim were within the range of 50 to 450 x 109/l for most patients. Of the 271 patients who received romiplostim in ITP clinical trials, 55 (20%) were age 65 and over, and 27 (10%) were 75 and over. No overall differences in safety or efficacy have been observed between older and younger patients in the placebo-controlled studies.

The safety and efficacy of romiplostim was evaluated in two placebo-controlled, double-blind studies in adults with ITP who had completed at least one treatment prior to study entry and are representative of the entire spectrum of such ITP patients. Study S1 (212) evaluated patients who were non-splenectomised and had an inadequate response or were intolerant to prior therapies. Patients had been diagnosed with ITP for approximately 2 years at the time of study entry. Patients had a median of 3 (range, 1 to 7) treatments for ITP prior to study entry. Prior treatments included corticosteroids (90% of all patients), immunoglobulins (76%), rituximab (29%), cytotoxic therapies (21%), danazol (11%), and azathioprine (5%). Patients had a median platelet count of 19 x 109/l at study entry. Study S2 (105) evaluated patients who were splenectomised and continued to have thrombocytopenia. Patients had been diagnosed with ITP for approximately 8 years at the time of study entry. In addition to a splenectomy, patients had a median of 6 (range, 3 to 10) treatments for ITP prior to study entry. Prior treatments included corticosteroids (98% of all patients), immunoglobulins (97%), rituximab (71%), danazol (37%), cytotoxic therapies (68%), and azathioprine (24%). Patients had a median platelet count of 14 x 109/l at study entry. Both studies were similarly designed. Patients (>= 18 years) were randomised in a 2:1 ratio to receive a starting dose of romiplostim 1 ug/kg or placebo. Patients received single subcutaneous weekly injections for 24 weeks. Doses were adjusted to maintain (50 to 200 x 109/l) platelet counts. In both studies, efficacy was determined by an increase in the proportion of patients who achieved a durable platelet response. The median average weekly dose for splenectomised patients was 3 ug/kg and for non-splenectomised patients was 2 ug/kg. A significantly higher proportion of patients receiving romiplostim achieved a durable platelet response compared to patients receiving placebo in both studies. Following the first 4-weeks of study romiplostim maintained platelet counts >= 50 x 109/l in between 50% to 70% of patients during the 6 month treatment period in the placebo-controlled studies. In the placebo group, 0% to 7% of patients were able achieve a platelet count response during the 6 months of treatment. A summary of the key efficacy endpoints is presented below.

In both placebo-controlled, double-blind studies, patients already receiving ITP medical therapies at a constant dosing schedule were allowed to continue receiving these medical treatments throughout the study (corticosteroids, danazol and/or azathioprine). Twenty-one non-splenectomised and 18 splenectomised patients received on-study ITP medical treatments (primarily corticosteroids) at the start of study. All (100%) splenectomised patients who were receiving romiplostim were able to reduce the dose by more than 25% or discontinue the concurrent ITP medical therapies by the end of the treatment period compared to 17% of placebo treated patients. Seventy-three percent of non-splenectomised patients receiving romiplostim were able to reduce the dose by more than 25% or discontinue concurrent ITP medical therapies by the end of the study compared to 50% of placebo treated patients (see section 4.5).

Across the entire ITP clinical programme an inverse relationship between bleeding events and platelet counts was observed. All clinically significant ( >= grade 3) bleeding events occurred at platelet counts < 30 x 109/l. All bleeding events >= grade 2 occurred at platelet counts < 50 x 109/l. No statistically significant differences in the overall incidence of bleeding events were observed between Nplate and placebo treated patients. In the two placebo-controlled studies, 9 patients reported a bleeding event that was considered serious (5 [6.0%] romiplostim, 4 [9.8%] placebo; Odds Ratio [romiplostim/placebo] = 0.59; 95% CI = (0.15, 2.31)). Bleeding events that were grade 2 or higher were reported by 15% of patients treated with romiplostim and 34% of patients treated with placebo (Odds Ratio; [romiplostim/placebo] = 0.35; 95% CI = (0.14, 0.85)).

The European Medicines Agency has deferred the obligation to submit the results of studies with Nplate in one or more subsets of the paediatric population in the treatment of immune thrombocytopenia (idiopathic thrombocytopenic purpura) (see section 4.2 for information on paediatric use).

Pharmacokinetic properties

The pharmacokinetics of romiplostim involved target-mediated disposition, which is presumably mediated by TPO receptors on platelets and other cells of the thrombopoietic lineage such as megakaryocytes.

After subcutaneous administration of 3 to 15 mg/kg romiplostim, maximum romiplostim serum levels in ITP patients were obtained after 7-50 hours (median 14 hours). The serum concentrations varied among patients and did not correlate with the dose administered. Romiplostim serum levels appear inversely related to platelet counts.

The volume of distribution of romiplostim following intravenous administration of romiplostim decreased nonlinearly from 122, 78.8, to 48.2 ml/kg for intravenous doses of 0.3, 1.0 and 10 mg/kg, respectively in healthy subjects. This non-linear decrease in volume of distribution is in line with the (megakaryocyte and platelet) target-mediated binding of romiplostim, which may be saturated at the higher doses applied.

Elimination half-life of romiplostim in ITP patients ranged from 1 to 34 days (median, 3.5 days). The elimination of serum romiplostim is in part dependent on the TPO receptor on platelets. As a result for a given dose, patients with high platelet counts are associated with low serum concentrations and vice versa. In another ITP clinical trial, no accumulation in serum concentrations was observed after 6 weekly doses of romiplostim (3 mg/kg).

Pharmacokinetics of romiplostim in patients with renal and hepatic impairment has not been investigated. Romiplostim pharmacokinetics appear not affected by age, weight and gender to a clinically significant extent.

Preclinical safety data

Multiple dose romiplostim toxicology studies were conducted in rats for 4 weeks and in monkeys for up to 6 months. In general, effects observed during these studies were related to the thrombopoietic activity of romiplostim and were similar regardless of study duration. Injection site reactions were also related to romiplostim administration. Myelofibrosis has been observed in the bone marrow of rats at all tested dose levels. In these studies, myelofibrosis was not observed in animals after a 4-week post- treatment recovery period, indicating reversibility. In 1-month rat and monkey toxicology studies, a mild decrease in red blood cell count, haematocrit and haemoglobin was observed. There was also a stimulatory effect on leukocyte production, as peripheral blood counts for neutrophils, lymphocytes, monocytes, and eosinophils were mildly increased. In the longer duration chronic monkey study, there was no effect on the erythroid and leukocytic lineages when romiplostim was administered for 6 months where the administration of romiplostim was decreased from thrice weekly to once weekly. Additionally, in the phase 3 pivotal studies, romiplostim did not affect the red blood cell and white blood cells lineages relative to placebo treated subjects. Due to the formation of neutralising antibodies pharmacodynamic effects of romiplostim in rats were often decreasing at prolonged duration of administration. Toxicokinetic studies showed no interaction of the antibodies with the measured concentrations. Although high doses were tested in the animal studies, due to differences between the laboratory species and humans with regard to the sensitivity for the pharmacodynamic effect of romiplostim and the effect of neutralising antibodies, safety margins cannot be reliably estimated.

The carcinogenic potential of romiplostim has not been evaluated. Therefore, the risk of potential carcinogenicity of romiplostim in humans remains unknown.

In all developmental studies neutralising antibodies were formed, which may have inhibited romiplostim effects. In embryo-foetal development studies in mice and rats, reductions in maternal body weight were found only in mice. In mice there was evidence of increased post-implantation loss. In a prenatal and postnatal development study in rats an increase of the duration of gestation and a slight increase in the incidence of peri-natal pup mortality was found. Romiplostim is known to cross the placental barrier in rats and may be transmitted from the mother to the developing foetus and stimulate foetal platelet production. Romiplostim had no observed effect on the fertility of rats.

PHARMACEUTICAL PARTICULARS

List of excipients

Mannitol (E421) Sucrose L-histidine Hydrochloric acid (for pH adjustment) Polysorbate 20

Incompatibilities

This medicinal product must not be mixed with other medicinal products, except those mentioned in section 6.6.

Shelf life

5 years. After reconstitution: Chemical and physical in-use stability has been demonstrated for 24 hours at 25degC and for 24 hours at 2degC - 8degC, when protected from light and kept in the original vial. From a microbiological point of view, the medicinal product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 25degC or 24 hours in a refrigerator (2degC - 8degC), protected from light.

Special precautions for storage

Store in a refrigerator (2degC - 8degC). Do not freeze. Store in the original carton in order to protect from light. May be temporarily removed from the refrigerator for a maximum period of 24 hours at room temperature (up to 25degC). For storage conditions after reconstitution of the medicinal product, see section 6.3.

Nature and contents of container

Carton containing 1 or 4 vials of 250 ug of romiplostim. Not all pack sizes may be marketed.

Special precautions for disposal and other handling

Nplate is a sterile but unpreserved medicinal product and is intended for single use only. Nplate should be reconstituted in accordance with good aseptic practice. Nplate 250 micrograms powder for solution for injection should be reconstituted with 0.72 ml sterile water for injections, yielding a deliverable volume of 0.5 ml. An additional overfill is included in each vial to ensure that 250 ug of romiplostim can be delivered. Sodium chloride solutions or bacteriostatic water should not be used when reconstituting the medicinal product. Water for injections should be injected into the vial. The vial contents may be swirled gently and inverted during dissolution. The vial should not be shaken or vigorously agitated. Generally, dissolution of Nplate takes less than 2 minutes. Visually inspect the solution for particulate matter and discolouration before administration. The reconstituted solution should be clear and colourless and should not be administered if particulate matter and/or discolouration are observed. For the storage condition after reconstitution of the medicinal product see section 6.3. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

MARKETING AUTHORISATION HOLDER

MARKETING AUTHORISATION NUMBER(S)

DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu

Initial or subsequent once weekly dose:	Weight * in kg x Dose in ug/kg = Individual patient dose in ug
Volume to administer:	Dose in ug x 1 ml 500 ug = Amount to inject in ml
Example:	75 kg patient is initiated at 1 ug/kg of romiplostim. The individual patient dose = 75 kg x 1 ug/kg = 75 ug The corresponding amount of Nplate solution to inject = 75 ug x 1 ml = 0.15 ml 500 ug
*Actual body weight at initiation of treatment should always be used when calculating dose of romiplostim. Future dose adjustments are based on changes in platelet counts only and made in 1 ug/kg increments (see table below).

Platelet count (x 10 9 /l)	Action
< 50	Increase once weekly dose by 1 mg/kg
> 150 for two consecutive weeks	Decrease once weekly dose by 1 mg/kg
> 250	Do not administer, continue to assess the platelet count weekly After the platelet count has fallen to < 150 x 10 9 /l, resume dosing with once weekly dose reduced by 1 mg/kg

	Study 1 non-splenectomised patients		Study 2 splenectomised patients		Combined studies 1 & 2
	romiplostim (n = 41)	Placebo (n = 21)	romiplostim (n = 42)	Placebo (n = 21)	romiplostim (n = 83)	Placebo (n = 42)
No. (%) patients with durable platelet response a	25 (61%)	1 (5%)	16 (38%)	0 (0%)	41 (50%)	1 (2%)
(95% CI)	(45%, 76%)	(0%, 24%)	(24%, 54%)	(0%, 16%)	(38%, 61%)	(0%, 13%)
p-value	< 0.0001		0.0013		< 0.0001
No. (%) patients with overall platelet response b	36 (88%)	3 (14%)	33 (79%)	0 (0%)	69 (83%)	3 (7%)
(95% CI)	(74%, 96%)	(3%, 36%)	(63%, 90%)	(0%, 16%)	(73%, 91%)	(2%, 20%)
p-value	< 0.0001		< 0.0001		< 0.0001
Mean no. weeks with platelet response c	15	1	12	0	14	1
(SD)	3.5	7.5	7.9	0.5	7.8	2.5
p-value	< 0.0001		< 0.0001		< 0.0001
No. (%) patients requiring rescue therapies d	8(20%)	13 (62%)	11 (26%)	12 (57%)	19 (23%)	25 (60%)
(95% CI)	(9%, 35%)	(38%, 82%)	(14%, 42%)	(34%, 78%)	(14%, 33%)	(43%, 74%)
p-value	0.001		0.0175		< 0.0001

	Study 1 non-splenectomised patients		Study 2 splenectomised patients		Combined studies 1 & 2
	romiplostim (n = 41)	Placebo (n = 21)	romiplostim (n = 42)	Placebo (n = 21)	romiplostim (n = 83)	Placebo (n = 42)
No. (%) patients with durable platelet response with stable dose e	21 (51%)	0 (0%)	13 (31%)	0 (0%)	34 (41%)		0 (0%)
(95% CI)	(35%, 67%)	(0%, 16%)	(18%, 47%)	(0%, 16%)	(30%, 52%)		(0%, 8%)
p-value	0.0001		0.0046		< 0.0001
a Durable platelet response was defined as weekly platelet count >= 50 x 10 9 /l for 6 or more times for study weeks 18-25 in the absence of rescue therapies any time during the treatment period. b Overall platelet response is defined as achieving durable or transient platelet responses. Transient platelet response was defined as weekly platelet count>= 50 x 10 9 /l for 4 or more times during study weeks 2-25 but without durable platelet response. Patient may not have a weekly response within 8 weeks after receiving any rescue medicinal products. c Number of weeks with platelet response is defined as number of weeks with platelet counts >=50 x 10 9 /l during study weeks 2-25. Patient may not have a weekly response within 8 weeks after receiving any rescue medicinal products. d Rescue therapies defined as any therapy administered to raise platelet counts. Patients requiring rescue medicinal products were not considered for durable platelet response. Rescue therapies allowed in the study were IVIG, platelet transfusions, anti-D immunoglobulin, and corticosteroids. e Stable dose defined as dose maintained within +- 1 ug/kg during the last 8 weeks of treatment.

ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

NAME OF THE MEDICINAL PRODUCT

QUALITATIVE AND QUANTITATIVE COMPOSITION